Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the EU / 2025-523018-10-00
Authorised, not yet recruiting Phase III

Evaluation of a New Pain Management Regime for Oocyte Pick-Up During Fertility Treatment

2025-523018-10-00 · tracked via the Priya Life Science EU tracker
Sponsor
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Anesthesia and Analgesia
Decision date
22/01/2026
Enrollment target
318
Sites
Belgium

Condition studied

Acute procedural pain associated with oocyte pick-up (oocyte retrieval) in women undergoing IVF/ART.

Investigational medicinal product(s)

XANAX 0,5 mg TablettenVoltaren Retard 75 mg tabletten met verlengde afgifte.Midazolam Viatris 5 mg/ml oplossing voor injectieDzuveo 30 micrograms sublingual tabletLinisol 2 % oplossing voor injectieDAFALGAN FORTE 1 g filmomhulde tabletten

Every trial of Sufentanil and Midazolam across our registers →

Eligibility

Age group
18-64 years
Sex
Female

Primary endpoint

Overall intra-procedural pain intensity during OPU, VAS 0–100 mm recorded every 2 minutes from first puncture to completion; primary derived measure (mean/median or VAS-AUC over time) per SAP.

Endpoint detail

Patient satisfaction with pain management at ~24 h post-OPU using APS-POQ-R., Post-OPU VAS pain at T0 (arrival in recovery), 30 min, 1 h, and discharge., Rescue analgesic use at home within 24 h (type/amount)., Nausea/vomiting incidence: pre-OPU, immediate post-OPU, 30 min, 1 h, discharge, and at 24 h., Respiratory depression/other AEs during and immediately after OPU (SpO₂, RR, clinical observation)., Vaginal bleeding (usual/less/more than usual)., Recovery metrics: time to discharge, procedure duration, number of oocytes retrieved, operator experience level., Hormonal/fertility markers: E2/FSH/LH/progesterone and follicle count (2 days pre-OPU); HCG 2 weeks post-ET; clinical pregnancy at ~7 weeks.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523018-10-00 on CTIS ↗ ← All trials in the EU